CA2872021C - Glucokinase activator compositions for the treatment of diabetes - Google Patents

Glucokinase activator compositions for the treatment of diabetes Download PDF

Info

Publication number
CA2872021C
CA2872021C CA2872021A CA2872021A CA2872021C CA 2872021 C CA2872021 C CA 2872021C CA 2872021 A CA2872021 A CA 2872021A CA 2872021 A CA2872021 A CA 2872021A CA 2872021 C CA2872021 C CA 2872021C
Authority
CA
Canada
Prior art keywords
insulin
diabetes
pharmaceutically acceptable
glucose
glucokinase activator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2872021A
Other languages
English (en)
French (fr)
Other versions
CA2872021A1 (en
Inventor
Maria Carmen Valcarce Lopez
Tung Fong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
vTv Therapeutics LLC
Original Assignee
vTv Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by vTv Therapeutics LLC filed Critical vTv Therapeutics LLC
Publication of CA2872021A1 publication Critical patent/CA2872021A1/en
Application granted granted Critical
Publication of CA2872021C publication Critical patent/CA2872021C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2872021A 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes Active CA2872021C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648110P 2012-05-17 2012-05-17
US61/648,110 2012-05-17
PCT/US2013/041076 WO2013173417A2 (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes

Publications (2)

Publication Number Publication Date
CA2872021A1 CA2872021A1 (en) 2013-11-21
CA2872021C true CA2872021C (en) 2022-08-16

Family

ID=48576527

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2872021A Active CA2872021C (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes

Country Status (16)

Country Link
US (3) US10004782B2 (enExample)
EP (1) EP2849776B1 (enExample)
JP (1) JP6234443B2 (enExample)
KR (2) KR20150013838A (enExample)
CN (2) CN118453592A (enExample)
AU (2) AU2013262895A1 (enExample)
BR (1) BR112014028622A2 (enExample)
CA (1) CA2872021C (enExample)
EA (1) EA201492109A1 (enExample)
ES (1) ES2878001T3 (enExample)
HK (1) HK1202458A1 (enExample)
IL (1) IL235484A0 (enExample)
IN (1) IN2014DN09554A (enExample)
MX (1) MX360304B (enExample)
SG (2) SG10201609644UA (enExample)
WO (1) WO2013173417A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ603614A (en) 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
CN118453592A (zh) 2012-05-17 2024-08-09 Vtv治疗有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
LT3804714T (lt) * 2018-05-31 2025-03-10 Hua Medicine (Shanghai) Ltd. Farmacinis derinys ir kompozicija, ir derinio preparatas, kurio sudėtyje yra gliukokinazės aktyvatorius ir biguanido hipoglikeminis vaistas, taip pat jų gamybos būdas ir panaudojimas
AU2019287437A1 (en) * 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US11872221B2 (en) 2020-01-31 2024-01-16 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator
WO2021151251A1 (en) * 2020-01-31 2021-08-05 Hua Medicine (Shanghai) Ltd. Treating treatment-resistant diabetes with glucokinase activator
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
AU2020451588A1 (en) * 2020-06-04 2023-01-19 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3185834A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CN116194442A (zh) * 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途
CN121202809A (zh) * 2020-06-08 2025-12-26 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途
CN115350268B (zh) * 2022-08-24 2025-02-11 深圳青澜生物技术有限公司 一种用于治疗糖尿病的制剂、微针及其制备工艺

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (enExample) 1973-09-19 1977-01-28 Semb
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
US6660716B1 (en) * 1999-06-21 2003-12-09 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
WO2005006614A1 (ja) * 2003-07-14 2005-01-20 Sony Corporation 情報提供方法
WO2005023766A1 (en) 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
PT1723128E (pt) 2004-01-06 2013-02-27 Novo Nordisk As Heteroaril-ureias e o seu uso como activadores da glicoquinase
JP2008502658A (ja) * 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
US20060246141A1 (en) 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en) 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
JP2009500378A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
CN101258137A (zh) * 2005-07-08 2008-09-03 诺沃-诺迪斯克有限公司 双环烷基脲葡糖激酶活化剂
KR20080024211A (ko) 2005-07-08 2008-03-17 노보 노르디스크 에이/에스 디시클로알킬 우레아 글루코키나제 활성제
BRPI0612996A2 (pt) 2005-07-14 2010-12-14 Novo Nordisk As ativadores de urÉia glucocinase
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8138185B2 (en) 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
EA018988B1 (ru) 2008-05-16 2013-12-30 Такеда Калифорния, Инк. Активаторы глюкокиназы
JP5731196B2 (ja) 2008-07-22 2015-06-10 株式会社クレハ 末端ハロゲン基含量が低減されたポリアリーレンスルフィドの製造方法
WO2010107610A1 (en) * 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
PL2419097T3 (pl) 2009-04-16 2014-02-28 Taisho Pharmaceutical Co Ltd Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy
KR101190957B1 (ko) 2009-08-25 2012-10-15 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
NZ603614A (en) 2010-05-26 2014-10-31 Transtech Pharma Llc Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
EP2392575A1 (en) * 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
CN118453592A (zh) * 2012-05-17 2024-08-09 Vtv治疗有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物
AU2014226292B2 (en) 2013-03-04 2018-10-04 Vtv Therapeutics Llc Solid compositions comprising a glucokinase activator and methods of making and using the same
WO2014137797A2 (en) 2013-03-04 2014-09-12 Transtech Pharma, Llc Stable glucokinase activator compositions

Also Published As

Publication number Publication date
MX360304B (es) 2018-10-29
JP2015517525A (ja) 2015-06-22
JP6234443B2 (ja) 2017-11-22
WO2013173417A3 (en) 2014-02-20
AU2013262895A1 (en) 2014-11-13
WO2013173417A2 (en) 2013-11-21
US10004782B2 (en) 2018-06-26
CN104349790A (zh) 2015-02-11
MX2014013105A (es) 2015-04-08
KR20150013838A (ko) 2015-02-05
EP2849776B1 (en) 2021-04-21
SG11201406987UA (en) 2014-12-30
SG10201609644UA (en) 2017-01-27
US20180311314A1 (en) 2018-11-01
BR112014028622A2 (pt) 2017-06-27
AU2017203835A1 (en) 2017-06-22
US10588943B2 (en) 2020-03-17
KR20210027547A (ko) 2021-03-10
KR102371364B1 (ko) 2022-03-07
HK1202458A1 (en) 2015-10-02
US10980861B2 (en) 2021-04-20
EP2849776A2 (en) 2015-03-25
IN2014DN09554A (enExample) 2015-07-17
EA201492109A1 (ru) 2015-07-30
US20200138909A1 (en) 2020-05-07
ES2878001T3 (es) 2021-11-18
US20140066372A1 (en) 2014-03-06
AU2017203835B2 (en) 2018-11-22
IL235484A0 (en) 2014-12-31
CA2872021A1 (en) 2013-11-21
CN118453592A (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
US10980861B2 (en) Glucokinase activator compositions for the treatment of diabetes
EP1741445B1 (en) Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
KR101694136B1 (ko) Ｓｇｌｔ２ 억제제, ｄｐｐ－ｉｖ 억제제 및 임의로 추가의 당뇨병 치료제를 포함하는 약제학적 조성물 및 이의 용도
JP5077786B2 (ja) 併用医薬
KR20130137628A (ko) 대사 장애를 치료하기 위한 약제학적 병용물
TW201406374A (zh) 用於治療代謝性疾病之醫藥組合
JP7266327B2 (ja) 高血糖症を処置する方法
JP7005050B2 (ja) 亜鉛塩、シクロ－ヒスプロおよび抗糖尿薬物を有効成分として含有する糖尿病の予防または治療用薬学的組成物
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
AU2020426356A1 (en) Treating treatment-resistant diabetes with glucokinase activator
HK40067219A (zh) 低剂量三联组合制剂
HK1254471B (zh) (r)-(+)-维拉帕米用於治疗高血糖的用途及其药学组合物
HK1102424B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1108359B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1102422B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1087623B (en) Combination of antidiabetic drugs
HK1087623A1 (en) Combination of antidiabetic drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180509

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250509

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250509